Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EQL Pharma ABOSTO:EQL +0.93%40 3-Year EBITDA Growth Rate is 17.00% as of Jun. 2026, which is 52% below its 10-year median of 35.50. GuruFocus rates OSTO:EQL with a GF Score™ of 40/100. The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, EQL Pharma AB ranks better than 63.91% on this metric.
During the past 12 months, EQL Pharma AB's average EBITDA Per Share Growth Rate was -79.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 33.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 42.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of EQL Pharma AB was 142.80% per year. The lowest was -21.20% per year. And the median was 35.50% per year.
EQL Pharma AB (OSTO:EQL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
EQL Pharma AB 3-Year EBITDA Growth Rate Related Terms
OSTO:EQL vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's 3-Year EBITDA Growth Rate falls into.
EQL Pharma AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.00% mean?
EQL Pharma AB (OSTO:EQL) has a 3-Year EBITDA Growth Rate of 17.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for EQL Pharma AB and its competitors. This is 52% below median its historical median of 35.50. According to the industry distribution chart, EQL Pharma AB ranks #292 out of 809 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is EQL Pharma AB's 3-Year EBITDA Growth Rate too high?
EQL Pharma AB's current 3-Year EBITDA Growth Rate of 17.00% is 52% below median its 10-year median of 35.50. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. EQL Pharma AB's value of 17.00% is 91% above this industry median. Based on the distribution chart, EQL Pharma AB ranks #292 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #292 out of 809 companies for 3-Year EBITDA Growth Rate. This puts EQL Pharma AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. EQL Pharma AB's value of 17.00% is 91% above this benchmark. While the company's 10-year median is 35.50 vs. the industry median of 8.90, EQL Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EQL Pharma AB's current 3-Year EBITDA Growth Rate of 17.00% is 91% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current 3-Year EBITDA Growth Rate is 17.00%, which is 52% below median its own 10-year median of 35.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current 3-Year EBITDA Growth Rate of 17.00%. The current 3-Year EBITDA Growth Rate is 17.00%, which is 52% below median its 10-year median of 35.50 and 91% above the Drug Manufacturers industry median of 8.90. EQL Pharma AB's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current 3-Year EBITDA Growth Rate is 17.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
40GF Score
Get the complete analysis for OSTO:EQL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
